1. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001;7:249-264.
2. Burrows GD, Maguire KP, Norman TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine : a review. J Clin Psychiatry 1998;59:Suppl 14. 4-7.
3. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry 1999;60:Suppl 4. 4-11.
4. Frazer A. Pharmacology of antidepressants. J Clin Psychopharmacol 1997;17:Suppl 1. 2S-18S.
5. Keck PE Jr, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998;59:Suppl 6. 74-81.
6. Kent JM. SNaRIs, NaSSAs, and NaRIs : new agents for the treatment of depression. Lancet 2000;355:911-918.
7. Lenox RH, McNamara RK, Papke RL, Manji HK. Neurobiology of lithium : an update. J Clin Psychiatry 1998;59:Suppl 6. 37-47.
8. Licht RW. Drug treatment of mania : a critical review. Acta Psychiatr Scand 1998;97(6):387-397.
9. Macdonald KJ, Young LT. Newer antiepileptic drugs in bipolar disorder : rationale for use and role in therapy. CNS Drugs 2002;16(8):549-562.
10. Masand PS, Gupta S. Selective serotonin-reuptake inhibitors : an update. Harv Rev Psychiatry 1999;7:69-84.
11. Sadock BJ, Sadock VA. Synopsis of Psychiatry 2003;9th ed. Philadelphia: Wiliams & Wilkins.
12. Schatzberg AF. Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 2000;61:Suppl 10. 31-38.
13. Schatzberg AF, Cole JO, DMH CD. Manual of clinical psychopharmacology 2003;4th ed. Washington: American Psychiatric Publishing, Inc.